Part of the promise of neutral antagonists stems from their reduced effects on basal CBR signalling, which should in theory result in overall reduced systemic inflammation (O'Keefe et al., 2022) and a reduction in rimonabant-like side effects which can include nausea, malaise and anxiety (Chambers et al., 2007; Jarbe et al., 2008; Sink et al., 2008; Gueye et al., 2016). Here, CNR1 is linked to Anxiety.